Results 21 to 30 of about 51,322 (300)
Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
Frontiers in Immunology, 2021 Background Bullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. As the main treatment for BP, systemic corticosteroids are often limited by their side effects.
Yihua Zhang +7 more
semanticscholar +1 more source
Risk of Serious Infections in Patients with Bullous Pemphigoid: A Population-based Cohort Study
Acta Dermato-Venereologica, 2023 Patients with bullous pemphigoid are susceptible to serious infections, which are the leading cause of death in these patients. The aims of this population-based cohort study were to investigate the incidence and spectrum of serious infections in ...
Tsung-Hsien Chang +4 more
doaj +1 more source
The global incidence of bullous pemphigoid: a systematic review and meta‐analysis
British Journal of Dermatology, 2021 Bullous pemphigoid (BP) is an autoimmune blistering disorder that mainly affects older people. Although the disease is associated with considerable morbidity and mortality, the burden of disease worldwide is unclear.
Matty Persson +5 more
semanticscholar +1 more source
Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid
Frontiers in Immunology, 2021 Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series.
S. M. Seyed Jafari +5 more
semanticscholar +1 more source
S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2020 (1) Department of Dermatology, University of Lübeck, Lübeck, Germany (2) Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany (3) Department of Dermatology, University Hospital Erlangen, Erlangen, Germany (4) Department of ...
Enno Schmidt +17 more
semanticscholar +1 more source
Bilateral localized bullous pemphigoid in a young adult patient: A case report
SAGE Open Medical Case Reports, 2023 Bullous pemphigoid is the most common autoimmune subepidermal blistering disease, which typically presents in the elderly. Localized bullous pemphigoid is a rare variant of bullous pemphigoid, with only about 100 cases reported up to date. In this report,
Pedram Nourmohammadpour +5 more
doaj +1 more source
British Journal of Dermatology, 2021 Dear Editor, Growing evidence suggests that SARS-CoV-2 vaccination is associated with a variety of cutaneous reactions, also including autoimmune-mediated conditions such as autoimmune blistering diseases such as bullous pemphigoid (BP).1,2 We report new-
T. Gambichler +15 more
semanticscholar +1 more source
SAGE Open Medical Case Reports, 2023 Bullous pemphigoid is an acquired autoimmune subepidermal blistering disease that can arise following exposure to systemic medication, referred to as drug-induced bullous pemphigoid.
Louise M Gresham, Mark G Kirchhof
doaj +1 more source
European Journal of Case Reports in Internal Medicine, 2022 Bullous pemphigoid is a rare autoimmune dermatologic disease that usually occurs in the elderly. Mucous membrane lesions occur in about 10–35% of patients and are almost always limited to the oral mucous membrane. Esophageal involvement is very rare (4% of cases) and usually presents with chest pain, dysphagia, and odynophagia, though patients are ...
Castelo Branco, Catarina +2 more
openaire +4 more sources